Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Financing Activities (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Cash from Financing Activities data on record, last reported at $115000.0 in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 25.0% year-over-year to $115000.0; the TTM value through Sep 2025 reached $304000.0, up 181.48%, while the annual FY2024 figure was $108000.0, 99.95% down from the prior year.
  • Cash from Financing Activities reached $115000.0 in Q3 2025 per ZNTL's latest filing, down from $189000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $236.6 million in Q2 2023 and bottomed at $7000.0 in Q1 2024.
  • Average Cash from Financing Activities over 4 years is $41.6 million, with a median of $341000.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: tumbled 100.0% in 2024, then surged 2600.0% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $49.7 million in 2022, then plummeted by 99.38% to $309000.0 in 2023, then plummeted by 70.23% to $92000.0 in 2024, then grew by 25.0% to $115000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $115000.0 in Q3 2025, $189000.0 in Q1 2025, and $92000.0 in Q3 2024.